2,2-dichloro-1,1,1-trifluoroethane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
hydrochlorofluorocarbon : An organochlorine compound derived from methane, ethane or propane that contains atoms of hydrogen, chlorine, fluorine, and carbon only. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 9385 |
| SCHEMBL ID | 65852 |
| MeSH ID | M0184780 |
| Synonym |
|---|
| dichlorotrifluoromethylmethane |
| ethane, 2,2-dichloro-1,1,1-trifluoro- |
| 2,2-dichloro-1,1,1-trifluoroethane |
| hydrochlorofluorocarbon 123 |
| 306-83-2 |
| freon 123 |
| fc 123 |
| r 123 |
| brn 1736763 |
| hcfc-123 |
| cfc-123 |
| ccris 7216 |
| refrigerant hcfc-123 |
| solkane 123 |
| chlorofluorocarbon 123 |
| hydrochlorofluorocarbon |
| refrigerant r 123 |
| dichloro(trifluoromethyl)methane |
| 1,1,1-trifluoro-2,2-dichloroethane |
| 1,1-dichloro-2,2,2-trifluoroethane |
| hsdb 6752 |
| dichlorotrifluoroethane |
| hfa 123 |
| hcfc 123 |
| einecs 206-190-3 |
| inchi=1/c2hcl2f3/c3-1(4)2(5,6)7/h1 |
| freon-123 |
| fc-123 |
| FT-0694949 |
| 2,2-dichloro-1,1,1-trifluoro-ethane |
| A820478 |
| D2384 |
| flon-123 |
| AKOS006228609 |
| 34077-87-7 |
| ec 206-190-3 |
| f 123 |
| khladon 123 |
| 6s7c791u3v , |
| unii-6s7c791u3v |
| FT-0606099 |
| SCHEMBL65852 |
| chcl2cf3 |
| hfa-123 |
| dichlorotrifluoroethane [hsdb] |
| 1,1,1-trifluorodichloroethane |
| genetron 123 |
| fluorocarbon 123 |
| cf3chcl2 |
| DTXSID7020712 |
| mfcd00042132 |
| J-018055 |
| Q1869625 |
| 2,2-dichloro-1,1,1-trifluoroethane (hcfc-123) |
The goal of this study was to develop a human physiologically based pharmacokinetic (PBPK) model for the chemical HCFC-123 (2,2-dichloro-1,1, 1,1-trifluoroethane) and its major metabolite, triffluoroacetic acid (TFA)
| Excerpt | Reference | Relevance |
|---|---|---|
| "The in vivo metabolic rate constants for the metabolism of the chlorofluorocarbon replacement 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123) were determined for both male and female rats with a physiologically based pharmacokinetic model." | ( Gas-uptake pharmacokinetics of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123). Anders, MW; Dekant, W; Loizou, GD; Urban, G, ) | 0.64 |
| " A physiologically based pharmacokinetic (PBPK) model was developed which included a gut compartment and a variable size fat compartment in addition to the standard flow-limited compartments." | ( Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: a physiologically based pharmacokinetic model in the male Fischer 344 rat. Fisher, JW; McDougal, JN; Vinegar, A; Williams, RJ, 1994) | 0.58 |
| "The goal of this study was to develop a human physiologically based pharmacokinetic (PBPK) model for the chemical HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and its major metabolite, trifluoroacetic acid (TFA)." | ( Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling. Fisher, JW; Jarabek, AM; McDougal, JN; Vinegar, A; Williams, RJ, 1996) | 0.5 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " A dose-response evaluation for the health risk assessment of the replacement chemical HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) is also presented to show an innovative use of physiologically based pharmacokinetic (PBPK) modeling." | ( Mechanistic insights aid the search for CFC substitutes: risk assessment of HCFC-123 as an example. Fisher, JW; Jarabek, AM; Lipscomb, JC; McDougal, JN; Rubenstein, R; Vinegar, A; Williams, RJ, 1994) | 0.51 |
| " Furthermore, given that the PBPK model adequately describes the kinetics of halothane in rats and humans and of HCFC-123 in rats, use of the human PBPK model is proposed for deriving dose-response estimates of human health risks in the absence of human kinetic data." | ( Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling. Fisher, JW; Jarabek, AM; McDougal, JN; Vinegar, A; Williams, RJ, 1996) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (57.89) | 18.2507 |
| 2000's | 12 (31.58) | 29.6817 |
| 2010's | 4 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 4 (8.89%) | 6.00% |
| Case Studies | 5 (11.11%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 36 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||